Digital Legends Entertainment (DLE) showcases its advanced multi-platform game development technology, focusing on high-performance 3D games that have gained significant market traction with nearly 2 million total downloads. The company emphasizes its competitive advantage in the $11 billion mobile gaming market, bolstered by endorsements from industry leaders and a robust management team. Additionally, Biofarma presents its research on caffeine pharmacology targeting treatments for asthma and neurodegenerative diseases, highlighting potential investments and pipeline developments.

1. Presentación de las Startups
Modera: Paris de l’Etraz

3. Javier Campos
David Canós
NOTIKUMI

19. Xavier Carrillo
DIGITAL LEGENDS

20. Company Overview
Spain Startup & Investor Summit
Madrid, 2012

21. DLE trusted by industry leaders
“What they have been able to accomplish in 2 weeks makes you forget that you are
watching it on a mobile device and think you are watching it on a game console”
Scott Forstall, SVP iOS iPhone, Apple Keynote
“Digital Legends was able to push the limits in the development of Icebreaker ”
Torsten Reil, CEO, Natural Motion on Icebreaker
21

22. Karisma: The most-advanced 3D game development
environment for multi-platform mobile devices
 Comprehensive development environment including
libraries, tools, game engine and diagnostics
 Completely OS and device agnostic: Supporting all
relevant mobile platforms, connected TVs as well as
Flash11 and browser (Chrome)
 Native performance for all popular mobile/portable
platforms
(iPhone/iPad, Android, Symbian, WinMo, Linux, Meego, B
ADA and PSP)
 Most agile in industry in supporting new devices and
graphics technology (e.g. OpenGL 2.0)
 Young code base (4 years) with zero legacy unlike
competitors: 100% optimized for mobile
Systematically 18 months ahead of closest competitors, very few competitors worldwide with access to similar high-
performance technology required to deliver high-end 3D games
22

23. Strong underlying KPIs confirm DLE’s ability to create successful
games
Battlefield Bad Company 2 (2010) Icebreaker (2011)
Total downloads since launch  Nearly 2 Million downloads in 7 Total downloads since launch  Over 200,000 paid
(in Million) months (in Million) downloads in under a month
 Consistently in top 10 adventure since launch
games, #1 globally for all apps in  Ranked 8 in USA, top 10 in 14
Christmas 2010 countries
 To be pushed by key US carriers  #2 for sports games on
(Xperia PLAY) in 2011 AppStore in June 2011
 iPad version (launched June 2011)  Rated 4+ of 5 on iTunes
already #1 in most key markets  Featured App (chosen by
(UK, Germany) Apple) in over 60 countries
 Featured App (chosen by Apple) in
over 60 countries Weeks since launch
Bruce Lee Dragon Warrior (2010) Kroll (2008)
Key figures (DLE)
Total installs since launch  Game played by close to 2,5  Close to 850,000 players
(in Million)  #1 in Japanese AppStore top 5
Million gamers  Nearly 10 Million players
 #1 in Japan and UK, #2 in in most European countries
USA, top 10 in major  Featured App (chosen by  One #1 game world wide
European countries, #1 in Apple) in over 60 countries  Three #1 games in Japan
Samsung Bada store  First OpenGLES 2.0 title  Five top 25 games in USA
 Multi-platform success story:  Samsung Bada #1 free
Across all platforms incl. downloads  15 awards and nominations
iPhone, iPad, Bada, Android  PocketGamer Silver, IMGA
and Xperia PLAY People’s Choice Awards
 iPad App of the week in June
2011
23
es based on publically available sources. All data per H1 2011

24. Explosive recent top line growth confirms major market
traction – growth to accelerate going forward
Revenue and EBITDA 2009-2014F (in € Million) Achievements
Revenues
EBITDA  10 Million players
Very high revenue growth

Endorsed and trusted
 by industry leaders
Best-in-class multi-platform
 technology platform
Top ranked in various
 App Stores
2009 2010 2011 2012F 2013F 2014F 2015F
24

25. Key value considerations
 Part of a $11 billion mobile gaming market opportunity
 Proprietary state-of-the-art technology
 Riding on top of key trends: mobile, 3D, multiplayer, multi-platform, multi-
screen, virtual goods, gamification
 Competitive advantage in addressing all platforms with the best 3D performance
 High-end games validated by customers, hardware vendors such as Apple, AMD and
Intel. as well as publishers such as EA, Disney and Natural Motion
 Highly skilled management with experienced R&D team
 Unique expertise and know-how to pioneer the development of games for new
generation devices like tablets, gaming handhelds and TV Set-top Boxes
25

26. THANK YOU!
Xavier Carrillo-Costa
CEO
xcc@digital-legends.com
26

28. Julio Castro
PALO BIOFARMA

29. New medicines based on the
Coffee Pharmacology
Company Presentation
Spain Startup & Investor Summit - Madrid
6-8 June 2012

30. Adenosine Receptors: The Basis of the
Caffeine Pharmacology
Hyperactivity Diuretic
CAFFEINE
Antiarrythmic Bronchodilation

31. Adenosine Receptors: The Basis of the
Caffeine Pharmacology
Caffeine exert a strong
bronch0dilatory effects in
humans: Potential new
therapies for asthma
Hyperactivity (A2a receptors)
People consuming high
Caffeine levels daily shows
less risk to develop
Neurodegenerative CAFFEINE
Diseases: Potential new
therapiest for Parkinson and
Alzheimer Diseases
Bronchodilation (A1 receptors)

32. Pipeline Status at the proposed
next financing round and Exit
2012 2013 2014
Phase Ia Phase I Phase IIa
completed completed completed
PBF-509:
PD Treatment
Phase I Phase IIa
IND Filed completed completed
PBF-680:
Asthma Treatment
Financing Round of 5Mio € seeked in two tranches: Company Exit
2,5 Mio. € 2013 to support Phase I clinical trials Company Value:
2,5 Mio. € 2014 to support Phase IIa clinical trials
150 Mio.€

33. Excellent Market Potential
RECENT DEALS
Projects involving adenosine receptors modulators originated over 50 deals and over $300
Billions investment from the Pharmaceutical companies in the last three years e.g:
- Vernalis/ Biogen deal on A2a antagonists for PD (15 Mio € upfront after Phase I)
- Synosia/Roche deal on A2a antagonists for PD (40 Mio € upfront after Phase IIa)
- Merck acquisition of Novacardia on A1 antagonist (350 Mio USD)
TARGET INDICATION MARKET
The therapeutic indications targeted by our programs represent high unmet
medical needs with an excellent market potential:
Estimated Peak Sales (in Mio €)
PBF-680 (Asthma): 3000
PBF-509 (Parkinson's Disease): 600

34. The Team
Management
• Julio Castro, PhD (CEO):
– PhD in Chemistry at the University of Konstanz, Germany (1998)
– > 10 years of pharmaceutical research experience (Bayer, Almirall and Oryzon Genomics)
• Juan Camacho, PhD (CSO)
– PhD in Chemistry at the University of Jena, Germany (1997)
– > 10 years of pharmaceutical research experience (IBML, Jenapharm)
• Nahomi Castro, PhD (Clinical Project Leader)
– PhD in Biology at the University of Frankfurt, Germany (2000)
– > 5 years of experience leading preclinical and clinical programs (Adavancell, Salutis)
• Jose Maria Echarri: (Board Member/Interim CFO)
– Graduated in economy and enterprise administration at the University of Barcelona
– Former CFO of Oryzon Genomics
– CEO of Inveready

35. All the elements of a successful Biotech
Specialized
Bio-investors
A well defined A well trained and
exit strategy well advised team
PALOBIOFARMA
Attractive Market A solid IP
Potential
A diversified
promising Pipeline of
competitive products

37. Pedro Álvarez
PANCRACIO